Advertisement

Molecular Medicine

, Volume 17, Issue 5–6, pp 397–403 | Cite as

HDAC Inhibition in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis

  • Jelena Vojinovic
  • Nemanja Damjanov
Review Article

Abstract

Rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) are heterogeneous autoimmune diseases characterized by chronic joint inflammation. Methotrexate is used as the gold standard to treat rheumatoid arthritis, yet there are many patients in whom the disease cannot be controlled or who experience unacceptable intolerance. Most of the biologics currently used are effective, but mostly if combined with methotrexate. Long-term possible side effects, such as impaired host defense mechanisms against infection and lymphoma, are distinct disadvantages and a major concern of anticytokine therapies. Parenteral administration is a problem, particularly in children. Thus, there is a need to explore new treatment options. Here we review the properties of histone deacetylase inhibitors (HDACi) as they apply to rheumatoid arthritis by looking at effects on cytokine production, T-cell differentiation and the function of macrophages, dendritic cells, osteoblasts, osteoclasts and synovial fibroblasts. We also review the safety and efficacy of givinostat (ITF 2357) in the treatment of systemic onset juvenile idiopathic arthritis (SOJIA) and its influence on the cytokine networks in SOJIA. Givinostat is an orally active HDACi which was given to children with SOJIA. After 12 wk of treatment, there were significant benefits, particularly in reducing the pain and arthritic component of the disease and decreasing the neutrophilia. CD40L, IL-1α and IFNγ in whole blood lysates decreased at wks 2 and 4 compared with baseline levels The clinical data are consistent with those from animal models of rheumatoid arthritis and suggest that trials with HDACi are promising as a safe oral alternative to anticytokines and methotrexate.

Notes

Acknowledgments

The clinical study of ITF2357 in SOJIA is registered in https://doi.org/clinicaltrial.gov under identifier NCT00570661 and complied with the Declaration of Helsinki, International Conference on Harmonisation and Good Clinical Practice Guidelines.

References

  1. 1.
    Imboden JB. (2009) The immunopathogenesis of rheumatoid arthritis. Annu. Rev. Pathol. 4:417–34.CrossRefGoogle Scholar
  2. 2.
    Choy EH, Panayi GS. (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344:907–16.CrossRefGoogle Scholar
  3. 3.
    Petty RE et al. (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31:390–92.PubMedGoogle Scholar
  4. 4.
    Brennan FM, McInnes IB. (2008) Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest.118:3537–45.CrossRefGoogle Scholar
  5. 5.
    Li X et al. (2010) The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem. Biophys. Res. Commun. 397:131–5.CrossRefGoogle Scholar
  6. 6.
    Tran CN et al. (2007) Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells. Am. J. Pathol. 171:1588–98.CrossRefGoogle Scholar
  7. 7.
    Cawston TE, Young DA. (2010) Proteinases involved in matrix turnover cartilage and bone breakdown. Cell Tissue Res. 339:221–35.CrossRefGoogle Scholar
  8. 8.
    Mangge H, hours, ovic J, Schauenstein K. (2002) Do chemokines spark autoimmunity in juvenile and adult rheumatic disease? Immunobiology. 206:459–71.CrossRefGoogle Scholar
  9. 9.
    Huber LC, Stanczyk J, Jüngel A, Gay S. (2007) Epigenetics in inflammatory rheumatic diseases. Arthritis Rheum. 56:3523–31.CrossRefGoogle Scholar
  10. 10.
    Jüngel A, Ospelt C, Gay S. (2010) What can we learn from epigenetics in the year 2009? Curr. Opin. Rheumatol. 22:284–92.CrossRefGoogle Scholar
  11. 11.
    Elaut G, Rogiers V, Vanhaecke T. (2007) The pharmaceutical potential of histone deacetylase inhibitors. Curr. Pharm. Des. 13:2584–620.CrossRefGoogle Scholar
  12. 12.
    Grabiec AM, et al. (2010) Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J. Immunol. 184:2718–28.CrossRefGoogle Scholar
  13. 13.
    Maciejewska Rodrigues H, Jungel A, Gay ER, Steffen G. (2009) Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis. Mol. Immunol. 47:12–8.CrossRefGoogle Scholar
  14. 14.
    Halili MA, Andrews MR, Sweet MJ, Fairlie DP. (2009) Histone deacetylase inhibitors in inflammatory disease. Curr. Top. Med. Chem. 9:309–19.CrossRefGoogle Scholar
  15. 15.
    Ermann J, Fathman CG. (2001) Autoimmune diseases: genes, bugs and failed regulation. Nat. Immunol. 2:759–61.CrossRefGoogle Scholar
  16. 16.
    Criswell LA. (2010) Gene discovery in rheumatoid arthritis highlights the CD40/NF-kappaB signaling pathway in disease pathogenesis. Immunol. Rev. 233:55–61.CrossRefGoogle Scholar
  17. 17.
    Bäckdahl L, Bushell A, Beck S. (2010) Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. Int. J. Biochem. Cell Biol. 41:176–84.CrossRefGoogle Scholar
  18. 18.
    Vojinovic J, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63:1452–8.CrossRefGoogle Scholar
  19. 19.
    Verbsky JW, White AJ. (2004) Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 31:2071–5.PubMedGoogle Scholar
  20. 20.
    Yokota S, et al. (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, doubleblind, placebo-controlled, withdrawal phase III trial. Lancet. 371:998–1006.CrossRefGoogle Scholar
  21. 21.
    Horneff G, et al. (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann. Rheum. Dis. 63:1638–44.CrossRefGoogle Scholar
  22. 22.
    Papagoras C, Voulgari PV, Drosos AA. (2010) Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Autoimmun. Rev. 9:574–82.CrossRefGoogle Scholar
  23. 23.
    Smolen JS, et al. (2010): EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69:964–75.CrossRefGoogle Scholar
  24. 24.
    Furlan A, et al. (2011) Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 17:353–362.CrossRefGoogle Scholar
  25. 25.
    Giannini EH, et al. (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 40:1202–9.CrossRefGoogle Scholar
  26. 26.
    Leoni F, et al. (2005) The histone deacetylase inhibitor ITF2357 reduces production of proinflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 11:1–15.CrossRefGoogle Scholar
  27. 27.
    Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201:1479–86.CrossRefGoogle Scholar
  28. 28.
    Goldbach-Mansky R, et al. (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 355:581–92.CrossRefGoogle Scholar
  29. 29.
    Lequerre T, et al. (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 67:302–8.CrossRefGoogle Scholar
  30. 30.
    Giannini EH, et al. (1992) Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N. Engl. J. Med. 326:1043–9.CrossRefGoogle Scholar
  31. 31.
    Vastert SJ, Kuis W, Grom AA. (2009) Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract. Res. Clin. Rheumatol. 23:655–64.CrossRefGoogle Scholar
  32. 32.
    Ruperto N, et al. (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 50:2191–201.CrossRefGoogle Scholar
  33. 33.
    Foel D, et al. (2010) Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA. 303:1266–73.CrossRefGoogle Scholar
  34. 34.
    Ilowite N, et al.(2009). Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin. Rheumatol. 28:129–37.CrossRefGoogle Scholar
  35. 35.
    Gattorno M, et al. (2008). The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58:1505–15.CrossRefGoogle Scholar
  36. 36.
    Peart MJ, et al. (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 102:3697–702.CrossRefGoogle Scholar
  37. 37.
    Blenchard F, Chipoy C. (2005) Histone deacetylase inhibitors: new drugs for the treatment of inflammatory disease. Drug Disc. Today. 10:197–204.CrossRefGoogle Scholar
  38. 38.
    Kawabata T, et al. (2010) Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res. Ther. 12:R133.CrossRefGoogle Scholar
  39. 39.
    Horiuchi M, et al. (2009) Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J. Rheumatol. 36:1580–9.CrossRefGoogle Scholar
  40. 40.
    Leoni F, et al. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. U.S.A. 99:2995–3000.CrossRefGoogle Scholar
  41. 41.
    Chung YL, Lee MY, Wang AJ, Yao LF. (2003) A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther. 8:707–17.CrossRefGoogle Scholar
  42. 42.
    Nishida K, et al. (2004) Histone deacetylase inhibitor suppression of autoantibody mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 50:3365–76.CrossRefGoogle Scholar
  43. 43.
    Lin HS, et al. (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150:862–72.CrossRefGoogle Scholar
  44. 44.
    Joosten LAB, Leoni F, Meghji S, Mascagni P. (2011) Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. Mol. Med. 17:391–396.CrossRefGoogle Scholar
  45. 45.
    Carta S, et al. (2006) Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood. 108:1618–26.CrossRefGoogle Scholar
  46. 46.
    Edens RE, Dagtas S, Gilbert KM. (2006) Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int. Immunopharmacol. 6:1673–81.CrossRefGoogle Scholar
  47. 47.
    Choo QY, Ho PC, Tanaka Y, Lin HS. (2010) Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-iB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatology. 49:1447–60.CrossRefGoogle Scholar
  48. 48.
    Brogdon JL, et al. (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood. 109:1123–30.CrossRefGoogle Scholar
  49. 49.
    Reddy P, et al. (2008) Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 118:2562–73.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Nencioni A, et al. (2007) Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin. Cancer Res.13:3933–41.CrossRefGoogle Scholar
  51. 51.
    Tao R, et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med.13:1299–307.CrossRefGoogle Scholar
  52. 52.
    Perlman H, et al. (2003) IL-6 and matrix metalloproteinase-1 are regulated by the cyclindependent kinase inhibitor p21 in synovial fibroblasts. J. Immunol.170:838–45.CrossRefGoogle Scholar
  53. 53.
    Wang Z, et al. (2009) SAHA-a potential epigenetic therapeutic agent for lung fibrosis? Eur. Respir. J. 34:145–55.CrossRefGoogle Scholar
  54. 54.
    Young DA, et al. (2005) Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthrit. Res. Ther. 7:R503–12.CrossRefGoogle Scholar
  55. 55.
    Nasu Y, et al. (2008) Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthr. Cartil.16:723–32.CrossRefGoogle Scholar
  56. 56.
    Manabe H, et al. (2008). Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts. Inflamm. Res. 57:4–10.CrossRefGoogle Scholar
  57. 57.
    Nakamura T, et al. (2005) Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J. Immunol. 175:5809–16.CrossRefGoogle Scholar
  58. 58.
    Suzuki T, et al. (2006) Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J. Med. Chem. 49:4809–12.CrossRefGoogle Scholar
  59. 59.
    Schroeder TM, Westendorf JJ. (2005) Histone deacetylase inhibitors promote osteoblast maturation. J. Bone Miner. Res. 20:2254–63.CrossRefGoogle Scholar
  60. 60.
    Lewis EC, et al. (2011) The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro. Mol. Med. 17:369–377.CrossRefGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2011

Authors and Affiliations

  1. 1.Clinic of Pediatrics, Department of Pediatric RheumatologyUniversity Clinic Center NisNisSerbia
  2. 2.Institute of RheumatologyBelgradeSerbia

Personalised recommendations